Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: One embodiment is a rotor system comprising a duct ring; a hub disposed centrally to the duct ring; first and second stators each connected between the duct ring and the hub; first and second control vanes rotatably connected to the first and second stators, respectively; a structural hoop having a first end connected to the first control vane and a second end connected to the second control vane, the structural hoop for translating rotation of the first control vane about a vane axis to the second control vane; and a mechanism for restricting at least one of forward-aft movement and side-to-side movement of the structural hoop relative to the duct ring.

Abstract: A novel self-cooling food and beverage container and a process for manufacturing the same is disclosed. A self-cooling beverage and food container using a substantive humidification cooling process within said food and beverage container for cooling food and beverage products is disclosed. Methods of assembling and operating the apparatus are disclosed.

Abstract: A novel self-cooling food product container apparatus and a process for manufacturing the same is disclosed. A self-cooling food product container combined with a substantive vapor transport system producing a humidification cooling process for cooling food and beverage products. Methods of assembling and operating the apparatus are also provided.

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: A system includes a thermal engine operatively connected to drive a propeller. An electric motor is operatively connected to the thermal engine to drive the propeller together with the thermal engine. An external input system is configured to accept input and output a thrust command. A protection function module is configured to enforce limits on the thermal engine, electric motor, and propeller. A low select module is operatively connected to receive input from the external input system and form the protection function module and to output the lower of input from the protection function module and external input system to the thermal engine, the electric motor, and the propeller.

Abstract: One embodiment is a rotor system comprising a duct ring; a hub disposed centrally to the duct ring; first and second stators each connected between the duct ring and the hub; first and second control vanes rotatably connected to the first and second stators, respectively; a structural hoop having a first end connected to the first control vane and a second end connected to the second control vane, the structural hoop for translating rotation of the first control vane about a vane axis to the second control vane; and a mechanism for restricting at least one of forward-aft movement and side-to-side movement of the structural hoop relative to the duct ring.

Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

Abstract: A control system for a hybrid electric powerplant of an aircraft can include a heat engine controller configured to receive one or more power settings and to determine a heat engine setting and an electric motor setting. The heat engine controller can be configured to use the heat engine setting to control a heat engine system as a function of the heat engine setting to control torque output by a heat engine. The heat engine controller can be configured to output the electric motor setting. The system can include an electric motor controller can be operatively connected to the heat engine controller. The electric motor controller configured to receive the electric motor engine setting from the heat engine controller and to control an electric motor system as a function of the electric motor setting to control torque output by an electric motor.

Abstract: A control system for a hybrid electric powerplant of an aircraft can include a throttle controller configured to receive one or more power settings and to output a heat engine setting and an electric motor setting, a heat engine controller operatively connected to the throttle controller. The heat engine controller can be configured to receive the heat engine setting and to control a heat engine system as a function of the heat engine setting to control torque output by a heat engine. The system can include a heat engine protection module that is part of or connected to the heat engine controller and configured to provide one or more protection commands to directly control one or more heat engine protection systems. The system can include an electric motor controller operatively connected to the throttle controller.

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.

Abstract: An ophthalmic device includes an optic including an optic axis and a closed-loop haptic structure coupled to the optic via a frame surrounding the optic, the closed-loop haptic structure including a closed loop extending from first and second attachment points to the frame. The closed loop includes a first hinge and a second hinge. The first hinge has a first section having a first component extending in a first angular direction, a second section having a second component extending in a second angular direction opposite to the first angular direction, and a first connecting section between the first section and the second section. The second hinge has a third section having a third component extending in the second angular direction, a fourth section having a fourth component extending in the first angular direction, the fourth section being connected to the second section to form the closed loop.

Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: A process for producing a glass melting component composed of refractory metal. A surface zone of the glass melting component is densified at least in sections by application of local compressive stress. As a result the surface zone has its porosity reduced compared to a volume section which is located underneath the surface zone and which has residual porosity.

Abstract: An ophthalmic device includes an optic including an optic axis and a closed-loop haptic structure coupled to the optic via a frame surrounding the optic, the closed-loop haptic structure including a closed loop extending from first and second attachment points to the frame. The closed loop includes a first hinge and a second hinge. The first hinge has a first section having a first component extending in a first angular direction, a second section having a second component extending in a second angular direction opposite to the first angular direction, and a first connecting section between the first section and the second section. The second hinge has a third section having a third component extending in the second angular direction, a fourth section having a fourth component extending in the first angular direction, the fourth section being connected to the second section to form the closed loop.

Abstract: The invention relates to a pharmaceutical combination according to the invention comprising an SSAO/VAP-1 inhibitor according to the formula (I) wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.

Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.